Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
The George Washington University
Headquarters: Washington, DC, United States of America
Website: http://www.gwu.edu
Year Founded: 1821
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Oct 21, 2022
Discovery & Translation
Oncorus’ synthetic RNA viruses for immunotherapy; plus Sisu’s small molecule for AML and more
BioCentury’s roundup of translational news
BioCentury | May 8, 2021
Targets & Mechanisms
Long COVID’s big tent needs to get more precise
Breaking the disease into subtypes will be important for getting more companies into the space
BioCentury | Jan 1, 2021
Targets & Mechanisms
A snapshot of target innovation in 2020
An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Aug 27, 2020
Distillery Therapeutics
Antisense oligos against transcription factor DUX4 for a muscular dystrophy
DISEASE CATEGORY: Musculoskeletal
INDICATION: Muscular dystrophy Antisense oligonucleotide therapies targeting DUX4 could treat facioscapulohumeral muscular dystrophy (FSHD), which is caused by
INDICATION: Muscular dystrophy Antisense oligonucleotide therapies targeting DUX4 could treat facioscapulohumeral muscular dystrophy (FSHD), which is caused by
BioCentury | Feb 28, 2019
Translation in Brief
Damming up metastasis
How platelet ‘decoys’ could prevent cancer metastasis
BioCentury | Jan 4, 2018
Strategy
Next generation resolutions
Charting FDA’s recent progress and ongoing campaigns in NGS diagnostics
BioCentury | Apr 13, 2017
Targets & Mechanisms
Cool and also collected
Thymosin α1 may be a rare one-stop shop for cystic fibrosis
Items per page:
1 - 10 of 34